Picture of Preveceutical Medical logo

PREV Preveceutical Medical Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m+1.29%
3m+21.09%
6m-13.84%
1yr-5.71%
Volume Change (%)
10d/3m-51.72%
Price vs... (%)
52w High-16.67%
50d MA+9.17%
200d MA+0.5%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Preveceutical Medical EPS forecast chart

Profile Summary

PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its Non-Addictive Analgesic is an engineering non-addictive analgesic peptide for pain management. Its Dual Gene Therapy targets type 2 diabetes and obesity. The Company’s subsidiary, PreveCeutical (Australia) Pty Ltd., manages its research programs.

Directors

    Last Annual
    December 31st, 2022
    Last Interim
    September 30th, 2023
    Incorporated
    July 31st, 2017
    Public Since
    December 30th, 2016
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    ca flag iconCanadian Securities Exchange
    Shares in Issue
    535,303,359

    PREV Share Price Performance

    Upcoming Events for PREV

    Similar to PREV

    Picture of 1933 Industries logo

    1933 Industries

    ca flag iconCanadian Securities Exchange

    Picture of 1CM logo

    1CM

    ca flag iconCanadian Securities Exchange

    Picture of Acreage Holdings logo

    Acreage Holdings

    ca flag iconCanadian Securities Exchange

    Picture of Adastra Holdings logo

    Adastra Holdings

    ca flag iconCanadian Securities Exchange

    Picture of Aion Therapeutic logo

    Aion Therapeutic

    ca flag iconCanadian Securities Exchange

    FAQ